Attached files
| file | filename |
|---|---|
| EX-31.2 - TearLab Corp | ex31-2.htm |
| EX-32.2 - TearLab Corp | ex32-2.htm |
| EX-32.1 - TearLab Corp | ex32-1.htm |
| EX-31.1 - TearLab Corp | ex31-1.htm |
| 10-K - TearLab Corp | form10-k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
| (1) | Registration Statement (Form S-1 Nos. 333-210326, 333-211102, and 333-220080) of TearLab Corporation; and | |
| (2) | Registration Statement (Form S-1 MEF No. 333-211103) of TearLab Corporation; and | |
| (3) | Registration Statement (Form S-3 Nos. 333-189372, 333-190116, 333-215886, and 333-201355) of TearLab Corporation; and | |
| (4) | Registration Statement (Form S-8 Nos. 333-124505, 333-155163, 333-181949, 333-189205, 333-191838, 333-195667, 333-196984, 333-197467, 333-199201, 333-201932 and 333-206757) pertaining to the 2014 Employee Stock Purchase Plan, 2002 Stock Option Plan, as amended, and Nonstatutory Stock Option Agreement of TearLab Corporation (formerly OccuLogix, Inc. and formerly Vascular Sciences Corporation); |
of our report dated March 2, 2018, with respect to the consolidated financial statements of TearLab Corporation included in this Annual Report (Form 10-K) of TearLab Corporation for the year ended December 31, 2017.
| /s/ Mayer Hoffman McCann P.C. | |
| San Diego, California | |
| March 2, 2018 |